StreetInsider.com News Articles

Jefferies Reiterates Buy Rating on Vera Therapeutics (VERA)

Tue, 02 Jun 2026 15:56:57 -0400

Jefferies analyst Farzin Haque reiterated a Buy rating and $60.00 price target on Vera Therapeutics (NASDAQ: VERA).

The analyst comments "VERA reached alignment w/ the FDA on an earlier ph.III eGFR analysis plan to support full approval -- eGFR data now expected in 3Q26 (vs prior 2-yr data in 1Q27) to support sBLA filing in 4Q26. Notably, this timing could place VERA roughly in-line w/ or potentially leapfrog Otsuka on full-approval. The eGFR narrative will be a key value proposition for robust uptake. VERA remains in quiet period pending accelerated approval (PDUFA on 7/7/26 w/ priority review)."

For an analyst ratings summary

William Blair on Vera Therapeutics (VERA): 'We believe this update has positive read-through to companies developing novel therapies for IgAN'

Tue, 02 Jun 2026 14:02:42 -0400

William Blair analyst Matt Phipps reiterated an Outperform rating and {REMOVEPT} price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "On Tuesday, June 2, Vera Therapeutics (VERA $32.09) announced that it had aligned with the FDA on an updated analysis plan for the Phase III ORIGIN 3 study of the APRIL/BAFF inhibitor atacicept in IgA nephropathy (IgAN). Originally, the typical two-year analysis of estimated glomerular filtration rate (eGFR) required to support full approval was expected to be completed in 2027, but Vera has aligned with the FDA on an earlier eGFR analysis, enabling a readout in the third quarter of

Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'

Tue, 02 Jun 2026 12:28:42 -0400

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "Fundamentally positive Vera for a few reasons (i) normally, Vera would need 96- week eGFR stabilization data to achieve full approval. In our view, this lowers the risk of eGFR failure, precluding the rare case that atacicept has waning efficacy over time (we do not believe this to be the case but this regulatory buy-in now avoids this scenario) (ii) this closes the gap on Otuska (Otsuka eGFR data sometime this year) (iii) it may be hard for Vertex (AA

Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'

Tue, 02 Jun 2026 12:28:42 -0400

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)

Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update'

Tue, 02 Jun 2026 11:15:55 -0400

Goldman Sachs analyst Paul Choi reiterated a Buy rating and $90.00 price target on Vera Therapeutics (NASDAQ: VERA).

The analyst comments "Earlier ORIGIN 3 eGFR analysis could support a full approval in 2027 for atacicept. We remain constructive on VERA shares following the announcement (link) that the company has reached alignment with the FDA to conduct the eGFR analysis (key secondary endpoint) for the Phase 3 ORIGIN 3 study of atacicept in 3Q26 instead of in 2027, which could meaningfully shrink the gap with Otsuka (covered by Akinori Ueda) whose eGFR results are expected in the June - August period (link).

Goldman Sachs on Vera Therapeutics (VERA): 'We are encouraged by today's update'

Tue, 02 Jun 2026 11:15:55 -0400

Goldman Sachs analyst Paul Choi reiterated a Buy rating and $90.00 price target on Vera Therapeutics (NASDAQ: VERA).

Raymond James: ''If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka'

Tue, 02 Jun 2026 10:12:40 -0400

Raymond James analyst Ryan Deschner reiterated a Strong Buy rating and $78.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "Vera announced it has alignment with FDA to carry out an earlier Phase 3 eGFR analysis to potentially support full approval for atacicept in IgAN. This analysis would be reported in 3Q26 (vs. 2027 prior), and moves up sBLA submission to 4Q26 and potential full approval to 2027 (vs. 2028 prior). If Vera is successful with this new plan, it could effectively shorten the theoretical lead Otsuka potentially has in achieving full approval in IgAN with a label that

TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'

Tue, 02 Jun 2026 07:16:06 -0400

TD Cowen analyst Ritu Baral reiterated a Buy rating and $73.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "New FDA alignment on ~12mo eGFR to support full ataci' IgAN approval (from prior 24mo) strengthens ataci's early commercial launch positioning in IgAN. Key catalysts now include, beyond the July 7 PDUFA, ~12mo Ph3 eGFR data in 3Q26 (possibly @ ASN), sBLA submission in 4Q26 with full approval likely we think in mid/late 2027. Launch prep remains on track; we have confidence in a clean approval."

For an analyst ratings summary and ratings history on Vera Therapeutics click here. For

Form 8-K Vera Therapeutics, Inc. For: Jun 02

Tue, 02 Jun 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26587318.html

Form 8-K Vera Therapeutics, Inc. For: Jun 02

Tue, 02 Jun 2026 07:05:00 -0400

si-local-file:///var/storage/secattach/20260602/26587318.html

Vera Therapeutics moves up atacicept analysis timeline with FDA agreement

Tue, 02 Jun 2026 07:00:16 -0400

Vera Therapeutics Inc. (NASDAQ: VERA) announced it has reached agreement with the U.S. Food and Drug Administration to accelerate the timeline for a key analysis supporting full approval of its drug candidate atacicept for IgA nephropathy treatment.

The company said the ORIGIN 3 eGFR analysis is now planned for the third quarter of 2026, moved forward from 2027. The eGFR measurement evaluates kidney function in patients with the autoimmune kidney disease.

Vera Therapeutics expects to receive a decision on accelerated approval for atacicept by July 7, 2026, under the Prescription Drug User Fee Act timeline. Following positive eGFR results, the company plans

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Tue, 02 Jun 2026 07:00:00 -0400

Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)
Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027
Pending positive eGFR analysis, plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026, with potential full approval in 2027

BRISBANE, Calif., June 02, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced it has aligned with

Vera Therapeutics Announces Alignment with U.S. FDA on Earlier ORIGIN Phase 3 Analysis to Support Potential Full Approval for Atacicept in Adults with IgA Nephropathy

Tue, 02 Jun 2026 07:00:00 -0400

Prescription Drug User Fee Act (PDUFA) date of July 7, 2026 for Biologics License Application (BLA) for accelerated approval of atacicept in patients with IgA Nephropathy (IgAN)
Revised ORIGIN 3 eGFR analysis now planned for Q3 2026, pulled forward from 2027
Pending positive eGFR analysis, plans to submit a supplemental Biologics License Application (sBLA) in Q4 2026, with potential full approval in 2027

Form 8-K Vera Therapeutics, Inc. For: May 21

Tue, 26 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260526/26550984.html

Form 8-K Vera Therapeutics, Inc. For: May 21

Tue, 26 May 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260526/26550984.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Morrison Scott W

Tue, 26 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260526/26550444.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Morrison Scott W

Tue, 26 May 2026 16:24:00 -0400

si-local-file:///var/storage/secattach/20260526/26550444.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Cheng Andrew

Tue, 26 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260526/26550423.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Cheng Andrew

Tue, 26 May 2026 16:23:00 -0400

si-local-file:///var/storage/secattach/20260526/26550423.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: SEIDENBERG BETH C

Tue, 26 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260526/26550402.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: SEIDENBERG BETH C

Tue, 26 May 2026 16:22:00 -0400

si-local-file:///var/storage/secattach/20260526/26550402.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Oliger Christy J.

Tue, 26 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260526/26550383.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Oliger Christy J.

Tue, 26 May 2026 16:21:00 -0400

si-local-file:///var/storage/secattach/20260526/26550383.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Meyers James R

Tue, 26 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260526/26550322.html

Form 4 Vera Therapeutics, Inc. For: May 21 Filed by: Meyers James R

Tue, 26 May 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260526/26550322.html